| Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers--The BELOW Study. | |
| | |
MedLine Citation:
|
PMID: 20354490 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The study was designed as a feasibility trial to evaluate the use of GP IIb/IIIa blockade in connection with drug eluting stents, bare stents and PTA only. Sixty patients with current ulcers were randomly assigned to receive abciximab plus a sirolimus coated stent (N.=14), abciximab plus a bare stent (N.=16), abciximab plus PTA (N.=14) and PTA alone (N.=19). Angiographic control was performed at two and six months. Recanalization was successful in all cases. Two month restenosis rate was 9%, 45.5%, 67% and 46%. At six month follow-up restenosis rate was 9%, 67%, 75% and 58%, respectively; 14% of all patients had major amputations within six months. Adjunctive administration of abciximab during peripheral arterial intervention below the knee was found to be safe. Sirolimus coated stent administration was followed by a higher patency rate. |
| | |
Authors:
|
G Tepe; J Schmehl; S Heller; K Brechtel; M Heuschmid; M Fenchel; U Kramer; S Miller; C D Claussen |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of cardiovascular surgery Volume: 51 ISSN: 0021-9509 ISO Abbreviation: J Cardiovasc Surg (Torino) Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-31 Completed Date: 2010-07-09 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 0066127 Medline TA: J Cardiovasc Surg (Torino) Country: Italy |
Other Details:
|
Languages: eng Pagination: 203-12 Citation Subset: IM |
Affiliation:
|
Institute for Diagnostic and Interventional Radiology Hospital of Rosenheim, Rosenheim, Germany. gunnar.tepe@kliro.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Amputation Angioplasty, Balloon / adverse effects, instrumentation* Antibodies, Monoclonal / adverse effects, therapeutic use* Cardiovascular Agents / administration & dosage* Drug-Eluting Stents* Feasibility Studies Female Humans Immunoglobulin Fab Fragments / adverse effects, therapeutic use* Leg Ulcer / drug therapy, physiopathology, radiography, therapy* Limb Salvage Lower Extremity / blood supply* Male Metals* Platelet Aggregation Inhibitors / adverse effects, therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Prospective Studies Prosthesis Design Recurrence Sirolimus / administration & dosage* Stents* Time Factors Treatment Outcome Vascular Patency |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Cardiovascular Agents; 0/Immunoglobulin Fab Fragments; 0/Metals; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 53123-88-9/Sirolimus; X85G7936GV/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The use of the cryoplasty technique in the treatment of infrapopliteal lesions for Critical Limb Isc...
Next Document: Developments in subintimal angioplasty in the infrainguinal segment.